CHONDROITIN SULFATE - A POTENTIAL BIODEGRADABLE CARRIER FOR COLON-SPECIFIC DRUG DELIVERY

被引:112
作者
RUBINSTEIN, A [1 ]
NAKAR, D [1 ]
SINTOV, A [1 ]
机构
[1] PERIO PROD LTD,IL-91237 JERUSALEM,ISRAEL
关键词
COLONIC DELIVERY; COLON; CHONDROITIN SULFATE; BIODEGRADATION; DRUG DELIVERY;
D O I
10.1016/0378-5173(92)90054-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chondroitin sulfate, a soluble mucopolysaccharide utilized as a substrate by the bacteroid inhabitants of the colon, was cross-linked and formulated in a matrix form with indomethacin as a drug marker. Three levels of cross-linkage were used. Cross-linkage was characterized qualitatively by IR spectral analysis and by UV absorbance shifts in hydroalcoholic solutions; it was also characterized quantitatively by comparing the amount of methylene blue remaining after adsorption (at equilibrium) onto the cross-linked product vs that remaining after adsorption onto untreated chondroitin. The indomethacin release kinetics from the various formulations was analyzed in phosphate-buffered saline (PBS) with and without rat caecal content at 37-degrees-C under a CO2 atmosphere. In separate experiments the caecal content was sonicated to cause lysis of the bacterial cell membranes. The drug release profiles indicated a constant rate of biodegradation in the presence of rat caecal content, and diffusion-driven release from the matrix's surface area in PBS control. Prolonged incubation in PBS with rat caecal content increased drug release, and by 28 h the released indomethacin levels were significantly higher than those in the PBS controls. The maximal cumulative percent release values for the PBS controls were: 30.1 +/- 10.0, 19.7 +/- 15.0, 9.0 +/- 4.1 for the three levels of cross-linkage of the chondroitin sulfate carriers, respectively, while those for the caecal content media were 71.0 +/- 19.0, 48.7 +/- 35.0, and 22.5 +/- 7.9, respectively. It was concluded that the indomethacin release from these systems was dependent upon the biodegradation action of the caecal content. The linear correlation between the degree of cross-linkage and the amount of drug released in the presence of caecal content suggests that drug release in the colon can be controlled by adjusting the relative amounts of the variously cross-linked chondroitin sulfate formulations in the matrices.
引用
收藏
页码:141 / 150
页数:10
相关论文
共 28 条
[1]   SOLUBLE FUNCTIONAL POLYMERS .3. A POLYMERIC DRUG FOR TREATMENT OF INFLAMMATORY BOWEL-DISEASE [J].
BROWN, JP ;
MCGARRAUGH, GV ;
PARKINSON, TM ;
WINGARD, RE ;
ONDERDONK, AB .
JOURNAL OF MEDICINAL CHEMISTRY, 1983, 26 (09) :1300-1307
[2]   BACTERIAL BIOFILMS IN NATURE AND DISEASE [J].
COSTERTON, JW ;
CHENG, KJ ;
GEESEY, GG ;
LADD, TI ;
NICKEL, JC ;
DASGUPTA, M ;
MARRIE, TJ .
ANNUAL REVIEW OF MICROBIOLOGY, 1987, 41 :435-464
[3]  
FARA JW, 1989, NOVEL DRUG DELIVERY AND ITS THERAPEUTIC APPLICATION, P103
[4]   DRUG GLYCOSIDES - POTENTIAL PRODRUGS FOR COLON-SPECIFIC DRUG DELIVERY [J].
FRIEND, DR ;
CHANG, GW .
JOURNAL OF MEDICINAL CHEMISTRY, 1985, 28 (01) :51-57
[5]   MACROMOLECULAR PRODRUGS .15. COLON-TARGETED DELIVERY - BIOAVAILABILITY OF NAPROXEN FROM ORALLY-ADMINISTERED DEXTRAN NAPROXEN ESTER PRODRUGS VARYING IN MOLECULAR-SIZE IN THE PIG [J].
HARBOE, E ;
LARSEN, C ;
JOHANSEN, M ;
OLESEN, HP .
PHARMACEUTICAL RESEARCH, 1989, 6 (11) :919-923
[6]  
HELLER J, 1987, CONTROLLED DRUG DELI, P179
[7]  
Ikesue K, 1991, P INT S CONTROL REL, V18, P580
[9]  
LARSEN C, 1991, ACTA PHARM NORDICA, V3, P41
[10]   MACROMOLECULAR PRODRUGS .16. COLON-TARGETED DELIVERY - COMPARISON OF THE RATE OF RELEASE OF NAPROXEN FROM DEXTRAN ESTER PRODRUGS IN HOMOGENATES OF VARIOUS SEGMENTS OF THE PIG GASTROINTESTINAL (GI) TRACT [J].
LARSEN, C ;
HARBOE, E ;
JOHANSEN, M ;
OLESEN, HP .
PHARMACEUTICAL RESEARCH, 1989, 6 (12) :995-999